Abstract 215P
Background
mnccRCC had a poor response to VEGF-targeted tyrosine kinase inhibitors (TKIs) and the first-line therapy was still limited. Our real-world study aimed to evaluate the effectiveness of tislelizumab-axitinib combination therapy versus TKI monotherapy as the first-line regimen in patients (pts) with mnccRCC.
Methods
Pts with mnccRCC received first-line therapy were identified between Jul. 2019 and Dec. 2022 in Sun Yat-sen University Cancer Center. Pts received first-line TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus axitinib therapy (T+A group). Baseline characteristics, objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were retrospectively collected. The differences on effectiveness between the two groups were compared.
Results
Totally 39 pts were included, with a median age of 46 (17-72) years. 77.1% had an IMDC intermediate/poor-risk disease. 53.8% had papillary RCC, 19.5% had Mit family translocation RCC, 12.1% had chromophobe RCC and others had unclassified RCC. The median follow-up was 23.7 (18.5-29.0) months. The T+A group (n=20) had a significantly longer PFS compared with the TKI group(n=19) (median PFS (95% CI): 11.0 (8.1-14.0) vs 4.6 (3.0-6.2) months, P<0.001). Similarly, ORR was remarkably improved in the T+A group (40.0% vs 10.5%, P=0.006). The PFS2 did not come to the significant difference between the T+A group and TKI group (median PFS2 (95% CI): 18.6 (NR-NR) vs 12.0 (7.9-16.2) months, P=0.646). Median OS was not reached for T+A group and TKI group (median OS (95% CI): NR vs 39.6 (NR-NR) months, P= 0.176).
Conclusions
Tislelizumab plus axitinib could be an effective first-line regimen option for mnccRCC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract